BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34989839)

  • 1. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure.
    Liu C; Shen Z; Ma H; Wang X; Wang X; Liu K; Wang X; Zhu Q; Zhao X
    Eur Radiol; 2022 May; 32(5):3006-3015. PubMed ID: 34989839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
    Liu C; Sun Y; Yang Y; Feng Y; Xie X; Qi L; Liu K; Wang X; Zhu Q; Zhao X
    Eur Radiol; 2021 Aug; 31(8):5840-5850. PubMed ID: 33533990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
    Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
    Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.
    Meng D; Liang C; Zheng Y; Wang X; Liu K; Lin Z; Zhu Q; Zhao X
    Eur Radiol; 2022 Dec; 32(12):8608-8616. PubMed ID: 35639146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
    Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
    Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
    Bonatti M; Valletta R; Zamboni GA; Lombardo F; Senoner M; Simioni M; Schifferle G; Bonatti G
    Eur Radiol; 2019 Jun; 29(6):2830-2836. PubMed ID: 30643946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T2-weighted imaging and dynamic contrast‑enhanced imaging in predicting the prognosis in patients with acute-on-chronic liver failure.
    Du YN; Guan CS; Lv ZB; Xue M; Xing YX; Xie RM
    BMC Gastroenterol; 2023 Aug; 23(1):285. PubMed ID: 37592280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of contrast-enhanced portal vein imaging at the hepatobiliary phase obtained with gadobenate dimeglumine for predicting decompensation and transplant-free survival in chronic liver disease.
    Cai S; Lin N; Yang Y; Ma W; Wang Y; Lin X; Wang X; Zhao X
    Eur Radiol; 2023 May; 33(5):3425-3434. PubMed ID: 36897349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
    Bonatti M; Valletta R; Avesani G; Lombardo F; Cannone F; Zamboni GA; Mansueto G; Manfredi R; Ferro F
    Eur Radiol; 2021 Apr; 31(4):2490-2496. PubMed ID: 33000303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.
    Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Sandström P; Brismar TB; Smedby O; Lundberg P
    Eur Radiol; 2012 Mar; 22(3):642-53. PubMed ID: 21984449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
    Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
    Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
    Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
    Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gadobenate dimeglumine and gadopentetate dimeglumine: a study of MR imaging and inductively coupled plasma atomic emission spectroscopy in rat brain tumors.
    Zhang T; Matsumura A; Yamamoto T; Yoshida F; Nose T; Shimojo N
    AJNR Am J Neuroradiol; 2002 Jan; 23(1):15-8. PubMed ID: 11827870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging.
    Kim YK; Lee JM; Kim CS; Chung GH; Kim CY; Kim IH
    Eur Radiol; 2005 Feb; 15(2):220-8. PubMed ID: 15624108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis.
    Li XM; Chen Z; Xiao EH; Shang QL; Ma C
    World J Gastroenterol; 2017 May; 23(17):3133-3141. PubMed ID: 28533670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
    Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
    Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.